SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2022 / Cilt: 6 - Sayı: 1

Prognostic Markers in the Treatment of Abiraterone Acetate + Prednisolone and Enzalutamide in Castration-Resistant Metastatic Prostate Cancer; Prognostic Value of Neutrophil Lymphocyte Ratio in Post - Docetaxel Setting

Erkan ERDUR
Ozgen Ahmet YİLDİRİM
Pages
45–49
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Methods: Patients whom progressed after at least 6 cycles of docetaxel chemotherapy, included.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To evaluate the relationship between the neutrophil lymphocyte ratio (NLR) and progression-free survival (PFS) at the start of enzalutamide or abiraterone acetate treatment in metastatic castration-resistant prostate cancer (mCRPC) at post-docetaxel setting.
📊
Key Findings & Data:Objectives: To evaluate the relationship between the neutrophil lymphocyte ratio (NLR) and progression-free survival (PFS) at the start of enzalutamide or abiraterone acetate treatment in metastatic castration-resistant prostate cancer (mCRPC) at post-docetaxel setting.
💡
Conclusion & Impact:Methods: Patients whom progressed after at least 6 cycles of docetaxel chemotherapy, included.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To evaluate the relationship between the neutrophil lymphocyte ratio (NLR) and progression-free survival (PFS) at the start of enzalutamide or abiraterone acetate treatment in metastatic castration-resistant prostate cancer (mCRPC) at post-docetaxel setting. Methods: Patients whom progressed after at least 6 cycles of docetaxel chemotherapy, included. Cases with

🔖

Cite This Article

ERDUR, E., YİLDİRİM, O. A. (2022). Prognostic Markers in the Treatment of Abiraterone Acetate + Prednisolone and Enzalutamide in Castration-Resistant Metastatic Prostate Cancer; Prognostic Value of Neutrophil Lymphocyte Ratio in Post - Docetaxel Setting. Eurasian Journal of Medical Investigation, Cilt: 6 - Sayı: 1, 45–49. https://ajindex.com/articles/508533

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al; ESMO Guidelines Committee. Electronic address: [email protected]. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:1119–34
  2. Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 2019;20:1730–9
  3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74
  4. Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther 2010;87:504–8. 5. de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, et al. Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer 2020;20:455–69
  5. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124
  6. Angkananard T, Anothaisintawee T, Thakkinstian A. P1791Neutrophil lymphocyte ratio and risks of cardiovascular diseases: a systematic review and meta-analysis. Eur Heart J 2017;38:ehx502.P1791
  7. Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol 2015;26:750–5
  8. Granot Z. Neutrophils as a therapeutic target in cancer. Front Immunol 2019;10:1710
  9. Wu L, Saxena S, Awaji M, Singh RK. Tumor-Associated Neutrophils in Cancer: Going Pro. Cancers (Basel) 2019;11:564
  10. Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature 2018;559:363–9
  11. Zhou T, Zeng SX, Ye DW, Wei Q, Zhang X, Huang YR, et al. Amulticenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer. PLos One 2015;10:e0117002
  12. Meisel A, von Felten S, Vogt DR, Liewen H, de Wit R, de Bono J, et al. Severe neutropenia during cabazitaxel treatment is associated with survival benefit i